![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
EMERZENE
Company Type: Therapeutics
Main focus: CRISPR-Cas, pain relief therapeutics
Company stage: Pre-clinical
Diseases: Pain
Genome-editing tool: CRISPR-Cas
Funding stage: Seed Funding
Location: California and Australia
Website: https://emerzene.com/
Pipeline: https://emerzene.com/pipeline/
Partners: Merck, NiST
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Emerzene_e948293e88_c4b70cf6bd.png)
Emerzene is a pre-clinical-stage company that employs CRISPR-Cas gene editing and cutting-edge farming techniques to engineer new strains of poppy. The final goal is to develop a new class of opioid-derived painkillers that do not induce addiction over a long period of time.